# Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling study

Source: [PLOS Medicine](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073) · 2026-11-17 · Medicine
Page: https://themorning.science/story/economic-value-of-gonorrhea-resistance-testing-in-the-united-states-a-multi-pers-bea206c2635106a2
Kind: research · Impact: medium

## In brief

- A multi-perspective modeling study assesses the economic value of gonorrhea resistance testing in the United States.
- Ceftriaxone is the only recommended first-line (empiric) treatment for gonorrhea, and rising antimicrobial resistance in Neisseria gonorrhoeae threatens its effectiveness.
- The study was published in PLOS Medicine on 2026-11-17 by Brooke E. Nichols, Betsy Wonderly Trainor, Grace Hampson, Yonatan H. Grad and Jeffrey D. Klausner.

## Why it matters

Because ceftriaxone is the only recommended empiric therapy for gonorrhea, knowing whether resistance testing is economically worthwhile informs how clinics and health systems decide where to spend on diagnostics to preserve treatment options.

## Timeline

- 2026-11-17: Study published in PLOS Medicine

## Coverage

- [Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling study](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005073) — PLOS Medicine, 2026-11-17

Tags: gonorrhea, antimicrobial resistance, ceftriaxone, sexually transmitted infections, health economics, diagnostic testing

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
